Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors

Therapy of metastatic melanoma advanced recently with the clinical implementation of signalling pathway inhibitors, such as vemurafenib, specifically targeting mutant BRAF(V600E). In general, patients experience remarkable clinical responses under BRAF inhibitor (BRAFi) treatment but eventually prog...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: López-Cobo, Sheila, Pieper, Natalia, Campos-Silva, Carmen, García-Cuesta, Eva M., Reyburn, Hugh T., Paschen, Annette, Valés-Gómez, Mar
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2017
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5749663/
https://ncbi.nlm.nih.gov/pubmed/29308322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1392426
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars